The forecast for antihypertensive medicine sales in Canada from 2024 to 2028 shows a stable trend, with sales projected to remain constant at $2.5 USD per capita annually. This indicates no year-on-year variation, suggesting a stable market with no expected growth or decline. In 2023, the data suggests that sales levels were also at $2.5 USD per capita, resulting in a 0% CAGR over the five-year period.

Future trends to watch for include:

Potential changes in healthcare policies that could impact drug pricing and accessibility.
Innovations in medication or treatment options that might influence market dynamics.
Demographic changes, particularly aging population trends, which could alter demand.
Increased awareness and preventive measures for hypertension, potentially affecting prescription rates.

Download as XLS

More about Antihypertensive Industry 2025-2029